Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca PLC

www.astrazeneca.com

Latest From AstraZeneca PLC

AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon

AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.

Drug Review Launches

Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic

The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.

Financing StartUps and SMEs

AstraZeneca’s Imfinzi-Treme Checkpoint Inhibitor Combination Fails Again In NSCLC

The Phase III NEPTUNE lung cancer trial found the combination of Imfinzi and tremelimumab was no better than chemotherapy at extending overall survival. After repeat setbacks, AstraZeneca is now running out of opportunities to show its dual checkpoint blockade is effective in NSCLC.

Clinical Trials Companies

2018 Completed Clinical Trials: Change Is The New Constant

Trialtrove’s annual review of clinical trials initiated by industry sponsors is a useful gauge of the diversity and innovative potential of biopharma’s investments in R&D. This year’s report reveals that, while there are patterns of consistency in many aspects of the trial landscape, changes are in the wind – particularly as companies outside the pharma top 20 now contribute more completed trials than any other type of sponsor.

Clinical Trials Market Intelligence
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register